{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:06Z","timestamp":1786437006045,"version":"build-2736575974"},"reference-count":25,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>New psychoactive substances (NPS) are substances not controlled by UN conventions and they pose a threat to public health. The number of NPS on the recreational market is increasing each year. NPS are classified into six categories based on pharmacological properties: sedatives, opioids, stimulants, hallucinogens, dissociatives and cannabinoids. NPS are easily accessible, vary in potency and composition, and many clinicians lack experience in treating intoxications with these compounds. Monitoring of NPS is essential to update legislation, reduce exposure and guide clinical practice, as argued in this review.<\/jats:p>","DOI":"10.61409\/v10250795","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:21:42Z","timestamp":1779344502000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["New psychoactive substances"],"prefix":"10.61409","author":[{"given":"Dorte Fris","family":"Palmqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnar","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Schou","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref0","unstructured":"European Union Drugs Agency. New psychoactive substances (NPS). www.euda.europa.eu\/topics\/nps_en (16. jul 2025)"},{"key":"ref1","unstructured":"United Nations Office on Drugs and Crime. Early warning advisory on new psychoactive substances. www.unodc.org\/LSS\/Page\/NPS (17. jul 2025)"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Shafi A, Berry AJ, Sumnall H et al. New psychoactive substances: a review and updates. Ther Adv Psychopharmacol. 2020;10:2045125320967197. https:\/\/doi.org\/10.1177\/2045125320967197","DOI":"10.1177\/2045125320967197"},{"key":"ref3","unstructured":"Herold MD, Frank VA. Nye psykoaktive stoffer: en ny bekymring i det danske stoflandskab? STOF: tidsskrift for stofmisbrugsomr\u00e5det. 2018;30:25-28"},{"key":"ref4","unstructured":"Sundhedsstyrelsen. Nye psykoaktive stoffer i Danmark. \u00c5rsrapport 2024. www.sst.dk\/-\/media\/Udgivelser\/2025\/Stoffer\/Nye-psykoaktive-stoffer-aarsrapport-2024.ashx?sc_lang=da&hash=68C7EBEEB9F7744BE749080DB0EA5759 (29. jul 2025)"},{"key":"ref5","unstructured":"Afdeling for Retskemi Aarhus Universitet, Retskemisk Afdeling K\u00f8benhavns Universitet, Retskemisk Afdeling, Syddansk Universitet. Narkotika p\u00e5 gadeplan 2024. Rapport til Sundhedsstyrelsen. 2025. www.sst.dk\/-\/media\/Udgivelser\/2025\/Stoffer\/Narkotika-paa-gadeplan-2024.ashx?sc_lang=da&hash=84B5740005051A7038B1B82FD313310F (29. jul 2025)"},{"key":"ref6","unstructured":"European Union Drugs Agency. European Drug Report 2025: trends and developments. 2025. www.euda.europa.eu\/publications\/european-drug-report\/2025_en (19. sep 2025)"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Peacock A, Bruno R, Gisev N et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668-1684. https:\/\/doi.org\/10.1016\/S0140-6736(19)32231-7","DOI":"10.1016\/S0140-6736(19)32231-7"},{"key":"ref8","unstructured":"European Union Drugs Agency. EU drug market: new psychoactive substances - in-depth analysis. European Union Drugs Agency, 2024. www.euda.europa.eu\/publications\/eu-drug-markets\/new-psychoactive-substances_en (30. jul 2025)"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Orsolini L, Corkery JM, Chiappini S et al. 'New\/designer benzodiazepines': an analysis of the literature and psychonauts' trip reports. Curr Neuropharmacol. 2020;18(9):809-837. https:\/\/doi.org\/10.2174\/1570159X18666200110121333","DOI":"10.2174\/1570159X18666200110121333"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Tracy DK, Wood DM, Baumeister D. Novel psychoactive substances: types, mechanisms of action, and effects. BMJ. 2017;356:i6848. https:\/\/doi.org\/10.1136\/bmj.i6848","DOI":"10.1136\/bmj.i6848"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Blakey K, Thompson A, Matheson A et al. What's in fake \"Xanax\"?: a dosage survey of designer benzodiazepines in counterfeit pharmaceutical tablets. Drug Test Anal. 2022;14(3):525-530. https:\/\/doi.org\/10.1002\/dta.3119","DOI":"10.1002\/dta.3119"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Albores-Garc\u00eda D, Cruz SL. Fentanyl and other new psychoactive synthetic opioids: challenges to prevention and treatment. Rev Invest Clin. 2023;75(3):93-104. https:\/\/doi.org\/10.24875\/RIC.23000109","DOI":"10.24875\/RIC.23000109"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Pergolizzi Jr J, Raffa R, LeQuang JAK et al. Old drugs and new challenges: a narrative review of nitazenes. Cureus. 2023;15(6):e40736. https:\/\/doi.org\/10.7759\/cureus.40736","DOI":"10.7759\/cureus.40736"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Holland A, Copeland CS, Shorter GW et al. Nitazenes - heralding a second wave for the UK drug-related death crisis? Lancet Public Health. 2024;9(2):e71-e72. https:\/\/doi.org\/10.1016\/S2468-2667(24)00001-X","DOI":"10.1016\/S2468-2667(24)00001-X"},{"key":"ref15","unstructured":"Sundhedsstyrelsen. Sundhedsstyrelsen advarer om farlige nitazener i falske OxyContin blisterpakker. Sundhedsstyrelsen, 2025. www.sst.dk\/da\/nyheder\/2025\/Sundhedsstyrelsen-advarer-om-farlige-nitazener-i-falske-OxyContin-blisterpakker (31. jul 2025)"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Berger JC, Severe AD, Jalloh MS et al. Naloxone dosing and hospitalization for nitazene overdose: a scoping review. J Med Toxicol. 2025;21(2):276-283. https:\/\/doi.org\/10.1007\/s13181-025-01059-8","DOI":"10.1007\/s13181-025-01059-8"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Andreasen MF, Telving R, Rosendal I et al. A fatal poisoning involving 25C-NBOMe. Forensic Sci Int. 2015;251:e1-e8. https:\/\/doi.org\/10.1016\/j.forsciint.2015.03.012","DOI":"10.1016\/j.forsciint.2015.03.012"},{"key":"ref18","unstructured":"Institut for Retsmedicin, Aarhus Universitet. National kortl\u00e6gning af rusmidler i spildevand fra danske byer. Aarhus Universitet, 2025. www.sst.dk\/-\/media\/Opioider\/Vidensbank\/National-kortlaegning-af-rusmidler-i-spildevand-fra-danske-byer.ashx (19. sep 2025)"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"H\u00f8ybye M, Bjerrum F, Reiter N. Ketamininduceret kolangiopati. Ugeskr L\u00e6ger. 2025;187:V09240631. https:\/\/doi.org\/10.61409\/V09240631","DOI":"10.61409\/V09240631"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen CF, Rasmussen BS, Linnet K et al. Emergence of semi-synthetic cannabinoids in cannabis products seized in Eastern Denmark over a 6-year period. J Forensic Sci. 2024;69(6):2009-2017. https:\/\/doi.org\/10.1111\/1556-4029.15631","DOI":"10.1111\/1556-4029.15631"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Alves VL, Gon\u00e7alves JL, Aguiar J et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359-382. https:\/\/doi.org\/10.1080\/10408444.2020.1762539","DOI":"10.1080\/10408444.2020.1762539"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Reiter N, Linnet K, Andersen N\u00d8 et al. Sv\u00e6r forgiftning med semisyntetiske cannabinoider. Ugeskr L\u00e6ger. 2024;186:V04240241. https:\/\/doi.org\/10.61409\/V04240241","DOI":"10.61409\/V04240241"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Thomsen R, Axelsen TM, L\u00f8kken N et al. Prolonged sedation and unconsciousness after intoxication with the novel semisynthetic cannabinoid hexahydrocannabioctyl (HHC-C8): two case descriptions. Toxicol Rep. 2025;14:101912. https:\/\/doi.org\/10.1016\/j.toxrep.2025.101912","DOI":"10.1016\/j.toxrep.2025.101912"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Reiter N, Palmqvist DF, Larsen GB et al. Long-lasting cognitive and physical impairment after recreational use of the semisynthetic cannabinoid hexahydrocannabinonyl (HHC-C9): a case report. Reports (MDPI). 2025;8(3):176. https:\/\/doi.org\/10.3390\/reports8030176","DOI":"10.3390\/reports8030176"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:00:21Z","timestamp":1786435221000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V10250795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":25,"URL":"https:\/\/doi.org\/10.61409\/v10250795","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}